Could microtubule inhibitors be the best choice of therapy in gastric cancer with high immune activity: mutant DYNC1H1 as a biomarker

Immune checkpoint blockade (ICB) has achieved unprecedented breakthroughs in various cancers, including gastric cancer (GC) with high immune activity (MSI-H or TMB-H), yet clinical benefits from ICB were moderate. Here we aimed to identify the most appropriate drugs which can improve outcomes in GC....

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Jin, Yang, BoWen, Shi, Ruichuan, Shao, Xinye, Yang, Yujing, Wang, Fang, Xiao, Jiawen, Qu, Xiujuan, Liu, Yunpeng, Zhang, Ye, Li, Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803585/
https://www.ncbi.nlm.nih.gov/pubmed/33221769
http://dx.doi.org/10.18632/aging.104084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803585/
https://www.ncbi.nlm.nih.gov/pubmed/33221769
http://dx.doi.org/10.18632/aging.104084

Ejemplares similares